Abstract: Pre-eclampsia (PE) is a common idiopathic disease occurring in pregnant women after 20 weeks of gestation. It changes rapidly, and the probability of serious complications of HELLP syndrome, placental abruption, preeclampsia, preterm birth, and fetal distress is high. PE is one of the leading causes of poor pregnancy outcomes in developing countries, and currently there is a lack of effective prevention and control measures. The basic pathological change of preeclampsia is systemic arteriospasm resulting in the poor erosion of gestational trophoblast, and shallow placental implantation, syncytio cells are ischemic and anoxic, inflammatory factor and procoagulant release, the blood pressure is raised, and the blood coagulation and fibrinolysis system are unbalanced, the blood is hypercoagulable in the early stage of the disease. Low molecular weight heparin (LMWH) and aspirin are two kinds of anticoagulant drugs commonly used in obstetrics. The coagulation state of preeclampsia is different from that of normal pregnant women, so the application of LMWH and aspirin in PE has attracted the attention of scholars all over the world. In this paper, the research progress on the effectiveness and safety of the two drugs in the prevention and treatment of PE will be reviewed.

Key words: Pre-eclampsia, Aspirin, Heparin, low-molecular-weight, Therapy, Prevention